The Company's management forecasts PGF's consolidated sales
to exceed PLN 5 billion in 2008 with double digit yoy NP growth.
Additionally, it maintains ambitious acquisition plans with entrance
into two new foreign markets. The acquisitions will be financed
via gaining investors at least to one of PGF's subsidiaries (it could
happen most likely in 2H08). Additionally, PGF plans to introduce
its subsidiary Pharmena into a NewConnect in order to finance
clinical tests of new molecule (it could happen rather in 1H08).